The derangement of BCL2 regulated control mechanisms is a defining characteristic of certain malignancies including subsets of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia [4]. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.